A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 [tramadol] and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)

Trial Profile

A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 [tramadol] and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Dec 2009

At a glance

  • Drugs Tramadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 11 Aug 2008 Status changed to recruiting according to Purdue Pharma.
    • 24 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top